Literature DB >> 23589739

Understanding the reasons behind the low utilisation of thrombolysis in stroke.

Ashraf Eissa1, Ines Krass, Christopher Levi, Jonathan Sturm, Rabsima Ibrahim, Beata Bajorek.   

Abstract

BACKGROUND: Thrombolysis remains the only approved therapy for acute ischaemic stroke (AIS); however, its utilisation is reported to be low. AIMS: This study aimed to determine the reasons for the low utilisation of thrombolysis in clinical practice.
METHOD: Five metropolitan hospitals comprising two tertiary referral centres and three district hospitals conducted a retrospective, cross-sectional study. Researchers identified patients discharged with a principal diagnosis of AIS over a 12-month time period (July 2009-July 2010), and reviewed the medical record of systematically chosen samples.
RESULTS: The research team reviewed a total of 521 records (48.8% females, mean age 74.4 ± 14 years, age range 5-102 years) from the 1261 AIS patients. Sixty-nine per cent of AIS patients failed to meet eligibility criteria to receive thrombolysis because individuals arrived at the hospital later than 4.5 hours after the onset of symptoms. The factors found to be positively associated with late arrival included confusion at onset, absence of a witness at onset and waiting for improvement of symptoms. However, factors negatively associated with late arrival encompassed facial droop, slurred speech and immediately calling an ambulance. Only 14.7% of the patients arriving within 4.5 hours received thrombolysis. The main reasons for exclusion included such factors as rapidly improving symptoms (28.2%), minor symptoms (17.2%), patient receiving therapeutic anticoagulation (6.7%) and severe stroke (5.5%).
CONCLUSION: A late patient presentation represents the most significant barrier to utilising thrombolysis in the acute stroke setting. Thrombolysis continues to be currently underutilised in potentially eligible patients, and additional research is needed to identify more precise criteria for selecting patients for thrombolysis.

Entities:  

Keywords:  Alteplase; Cerebrovascular accident; Stroke; Thrombolysis; Tissue Plasminogen Activator (tPA)

Year:  2013        PMID: 23589739      PMCID: PMC3626030          DOI: 10.4066/AMJ.2013.1607

Source DB:  PubMed          Journal:  Australas Med J        ISSN: 1836-1935


  22 in total

Review 1.  MR mismatch and thrombolysis: appealing but validation required.

Authors:  Stephen M Davis; Geoffrey A Donnan
Journal:  Stroke       Date:  2009-06-04       Impact factor: 7.914

2.  Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.

Authors:  Harold P Adams; Gregory del Zoppo; Mark J Alberts; Deepak L Bhatt; Lawrence Brass; Anthony Furlan; Robert L Grubb; Randall T Higashida; Edward C Jauch; Chelsea Kidwell; Patrick D Lyden; Lewis B Morgenstern; Adnan I Qureshi; Robert H Rosenwasser; Phillip A Scott; Eelco F M Wijdicks
Journal:  Stroke       Date:  2007-04-12       Impact factor: 7.914

3.  Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects.

Authors:  Stacy A Mangum; Kim R Kraenow; Warren A Narducci
Journal:  J Am Pharm Assoc (Wash)       Date:  2003 Jan-Feb

4.  Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10.

Authors:  Rae A Kokotailo; Michael D Hill
Journal:  Stroke       Date:  2005-07-14       Impact factor: 7.914

5.  Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment.

Authors:  P J Lindsberg; O Häppölä; M Kallela; L Valanne; M Kuisma; M Kaste
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

7.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

8.  Temporal trends in public awareness of stroke: warning signs, risk factors, and treatment.

Authors:  Dawn Kleindorfer; Jane Khoury; Joseph P Broderick; Eric Rademacher; Daniel Woo; Matthew L Flaherty; Kathleen Alwell; Charles J Moomaw; Alex Schneider; Arthur Pancioli; Rosie Miller; Brett M Kissela
Journal:  Stroke       Date:  2009-06-04       Impact factor: 7.914

9.  Improving access to acute stroke therapies: a controlled trial of organised pre-hospital and emergency care.

Authors:  Debbie A Quain; Mark W Parsons; Allan R Loudfoot; Neil J Spratt; Malcolm K Evans; Michelle L Russell; Angela T Royan; Andrea G Moore; Ferdinand Miteff; Carolyn J Hullick; John Attia; Patrick McElduff; Christopher R Levi
Journal:  Med J Aust       Date:  2008-10-20       Impact factor: 7.738

10.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

Authors:  Peter Sandercock; Joanna M Wardlaw; Richard I Lindley; Martin Dennis; Geoff Cohen; Gordon Murray; Karen Innes; Graham Venables; Anna Czlonkowska; Adam Kobayashi; Stefano Ricci; Veronica Murray; Eivind Berge; Karsten Bruins Slot; Graeme J Hankey; Manuel Correia; Andre Peeters; Karl Matz; Phillippe Lyrer; Gord Gubitz; Stephen J Phillips; Antonio Arauz
Journal:  Lancet       Date:  2012-05-23       Impact factor: 79.321

View more
  7 in total

Review 1.  Advances in medical revascularisation treatments in acute ischemic stroke.

Authors:  H Asadi; B Yan; R Dowling; S Wong; P Mitchell
Journal:  Thrombosis       Date:  2014-12-30

Review 2.  If Time Is Brain Where Is the Improvement in Prehospital Time after Stroke?

Authors:  Jeremy N Pulvers; John D G Watson
Journal:  Front Neurol       Date:  2017-11-20       Impact factor: 4.003

3.  Assessment of eligibility for thrombolysis in acute ischaemic stroke patients in Morocco.

Authors:  Mohamed Acherqui; Hajar Khattab; Younes Habtany; Rim Amzil; Salma Bellakhdar; Hicham El Otmani; Bouchra El Moutawakil; Mohammed Abdoh Rafai
Journal:  Pan Afr Med J       Date:  2020-08-26

4.  A Systematic Review and Meta-Analysis of Animal Studies Testing Intra-Arterial Chilled Infusates After Ischemic Stroke.

Authors:  Lane J Liddle; Christine A Dirks; Brittany A Fedor; Mohammed Almekhlafi; Frederick Colbourne
Journal:  Front Neurol       Date:  2021-01-06       Impact factor: 4.003

5.  A retrospective analysis of time delays in patients presenting with stroke to an academic emergency department.

Authors:  Diteboho Khalema; Lara N Goldstein; Susan Lucas
Journal:  SA J Radiol       Date:  2018-06-21

6.  Factors Associated with Shortening of Prehospital Delay among Patients with Acute Ischemic Stroke.

Authors:  Raúl Soto-Cámara; Josefa González-Santos; Jerónimo González-Bernal; Asunción Martín-Santidrian; Esther Cubo; José M Trejo-Gabriel-Galán
Journal:  J Clin Med       Date:  2019-10-17       Impact factor: 4.241

7.  Machine learning is a valid method for predicting prehospital delay after acute ischemic stroke.

Authors:  Li Yang; Qinqin Liu; Qiuli Zhao; Xuemei Zhu; Ling Wang
Journal:  Brain Behav       Date:  2020-08-18       Impact factor: 2.708

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.